ArticleVaccines2026
Systemic Transcriptional Responses to Clinical Vaccine Formulations and Live-Attenuated Vaccination: Comparative Kinetics and Hypotheses for Therapeutic Cancer Vaccine Monitoring.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01204684 (A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen +/- Toll-like Receptor Agonists for the Treatment of Malignant Glioma), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen +/- Toll-like Receptor Agonists for the Treatment of Malignant Glioma
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesTherapeutic cancer vaccination requires innate sensing, antigen presentation, lymphocyte priming, tumor access, cytotoxicity, and persistence. Prophylactic studies cannot demonstrate these antitumor functions but can compare systemic formulation responses. We tested whether blood transcription extended beyond innate responses to cancer-immunity-cycle programs.
methodsFrom 385 GEO records, we retained six human blood cohorts (five bulk-RNA and one sorted-cell) and one mouse blood/lymph-node study. We percentile-ranked 23 modules and compared baseline changes across 17 formulation questions. A separate screen of 35 poly-ICLC cancer-vaccine studies yielded NCT01204684; all arms received a tumor-lysate-pulsed dendritic-cell vaccine.
resultsAt 24 h after dose 2, AS01B, AS01E, and AS03 increased type I interferon-associated transcription relative to aluminum salt; the AS04 change was negligible. MF59 increased this score by 3.2 points (95% confidence interval, 1.2-5.1) relative to unadjuvanted antigen. Responsive comparisons also showed higher transcription of genes associated with antigen-presenting-cell costimulation, type 1 conventional dendritic cells, and MHC-I antigen processing/presentation. Yellow fever 17D produced a multicomponent trajectory, but the comparison did not isolate viral replication, antigen persistence, viral sensing, or tissue distribution. Of 390 evaluable module-formulation combinations, 278 had no result after false discovery rate (FDR) correction. Sensitivity estimates agreed (r = 0.998; 97.8% directional agreement). In NCT01204684, poly-ICLC recipients showed within-arm interferon and antigen-processing changes, but none of 46 agonist-versus-placebo module contrasts survived FDR correction.
conclusionsEarly systemic transcription differed among formulations, whereas later cancer-immunity programs were infrequently detected in bulk blood RNA. Therapeutic studies should add draining-node or tumor measurements and antigen-specific functional assays.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.